ADMA Biologics Q3 EPS $0.01 Beats $(0.01) Estimate, Sales $67.28M Beat $62.12M Estimate
Portfolio Pulse from totan@benzinga.com
ADMA Biologics reported Q3 earnings of $0.01 per share, beating the analyst consensus estimate of $(0.01) by 200 percent. This is a 112.5 percent increase over losses of $(0.08) per share from the same period last year. The company also reported quarterly sales of $67.28 million, beating the analyst consensus estimate of $62.12 million by 8.30 percent, a 63.73 percent increase over sales of $41.09 million the same period last year.
November 08, 2023 | 9:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ADMA Biologics reported strong Q3 earnings and sales, both beating analyst estimates. This positive financial performance could potentially boost the company's stock in the short term.
ADMA Biologics reported a significant increase in earnings and sales compared to the same period last year, and both figures beat analyst estimates. This strong financial performance indicates a positive outlook for the company, which could potentially lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100